Procedures
Tumors
TUMORS
Stage III NSCLCm+ received 2 to 4 cycles (each cycle lasted 4 weeks) administration of neoadjuvant Afatinib (Giotrif ®, Boehringer-Ingelheim Pharma GmbH, Ingelheim, Germany) therapy (NAT) (oral Afatinib 40 mg, once-daily). Chest CT was performed at the 8th and/or 16th weeks after Afatinib treatment. All CT scans of participants were assessed by the same radiologist and 3 experienced thoracic surgeons via Response Evaluation Criteria in Solid Tumors measurement criteria (RECIST, version 1.1). Radiologically PR or responder were defined as at least a 30% decrease in the sum of diameters of target lesions versus baseline